| アブストラクト | PURPOSE: There is currently no systematically available information available on how rapidly a specific lot of vaccine is used once distributed. We used data from reports to the Vaccine Adverse Event Reporting System (VAERS) to develop a proxy means of surveillance for the lifecycle of selected vaccine lots. METHODS: A convenience sample, consisting of selected lots of: diphtheria, tetanus, and acellular pertussis (DTaP), Haemophilus influenzae type b (Hib), Hepatitis B, and varicella vaccines, was selected for lifecycle analysis. Assuming that circulation of a vaccine lot is proportional to vaccine-specific adverse event (AE) reporting for that vaccine type, we constructed Gamma distributed usage models and compared them with lot-specific VAERS reports to estimate the actual lifecycle of lots in the system. RESULTS: Evidence of lot circulation was detected within 1-2 months, and a peak was observed 3-4 months after the vaccine release date for most of the study vaccines. Ninety percent of the vaccine doses in each lot were estimated to be used within 5-9 months of distribution. The length of time a vaccine lot was in use ranged from 5 to 17 months from earliest vaccination date. CONCLUSIONS: Our modeled and inferred administration of the selected lots of different vaccines were concordant. This method may be useful for spatial and temporal tracking of vaccine lot utilization. |
|---|
| 投稿日 | 2005/01/22 |
|---|
| 投稿者 | Dayan, Gustavo H; Iskander, John; Glasser, John; English-Bullard, Roseanne; Fullerton, Kathleen E; Chen, Robert |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| 組織名 | Epidemiology and Surveillance Division, National Immunization Program, Centers;for Disease Control and Prevention, Atlanta, GA 30333, USA. gdayan@cdc.gov |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/15662715/ |
|---|
